Cullinan Therapeutics to present preclinical data for CLN-978

Cullinan Therapeutics (CGEM) announced the upcoming presentation of preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, at American College of Rheumatology, ACR, Convergence 2024, taking place in Washington, D.C. from November 14-19, 2024. “These preclinical data show that CLN-978 is a highly potent T cell engager that leads to deep B cell depletion, supporting the broad development of CLN-978 as a potential new therapeutic option for patients with autoimmune diseases,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “We look forward to continued collaboration with investigators and the patient community as we initiate our global Phase 1 clinical trial of CLN-978 in systemic lupus erythematosus and deliver on our mission to bring new standards of care to patients.”